Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$5.17
-4.6%
$4.72
$3.42
$6.91
$291.85M1.911.89 million shs1.39 million shs
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
$2.23
-3.0%
$1.62
$2.35
$11.55
$66.35M-0.39486,688 shs288,906 shs
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$4.92
+2.5%
$4.94
$3.50
$12.40
$303.85M1.42590,418 shs511,839 shs
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
$5.51
+0.2%
$4.78
$1.94
$6.28
$293.68M0.35595,756 shs2.47 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.00%+3.63%+20.98%+0.93%-10.86%
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
0.00%-6.30%+53.79%+88.98%-68.10%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
0.00%+4.58%+0.21%+3.45%-22.20%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
0.00%-0.36%+6.38%+42.86%+8.06%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.2114 of 5 stars
0.01.00.00.02.20.80.6
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
2.7396 of 5 stars
3.31.00.00.02.71.71.9
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3.777 of 5 stars
3.03.00.04.21.91.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.00
BuyN/AN/A
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
0.00
N/AN/AN/A
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
2.67
Moderate Buy$15.33211.65% Upside
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
2.00
Hold$12.00117.79% Upside

Current Analyst Ratings Breakdown

Latest ELYM, ACB, SCPH, and GLUE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/29/2025
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/25/2025
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$6.00
8/25/2025
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
8/8/2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell
(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M1.18$0.58 per share8.87$7.78 per share0.66
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
N/AN/AN/AN/A$3.90 per shareN/A
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$177.99M1.71N/AN/A$3.63 per share1.36
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
$36.33M8.08N/AN/A$0.27 per share20.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M-$0.19N/A11.75N/A-5.66%-1.49%-1.06%11/5/2025 (Estimated)
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
-$35.12M-$0.53N/AN/AN/A-47.03%-45.97%N/A
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$72.70M$0.3613.67N/AN/A13.58%9.95%6.42%11/6/2025 (Estimated)
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
-$85.15M-$1.81N/AN/AN/A-183.55%-1,647.86%-71.76%11/12/2025 (Estimated)

Latest ELYM, ACB, SCPH, and GLUE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$0.31-$0.15+$0.16-$0.15$7.23 million$23.19 million
8/7/2025Q2 2025
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
-$0.30-$0.34-$0.04-$0.34$15.41 million$16.04 million
8/6/2025Q1 2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.18-$0.19-$0.37-$0.20$96.83 million$71.98 million
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
N/AN/AN/AN/AN/A
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/AN/AN/AN/AN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.06
2.97
1.51
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
N/A
60.41
60.41
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/A
7.16
7.16
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3.86
3.85
3.14

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
69.76%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
79.96%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
89.52%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
4.70%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
6.50%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
4.78%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13056.45 million56.45 millionOptionable
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
929.75 million28.35 millionNot Optionable
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
9061.76 million57.75 millionOptionable
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3053.30 million50.75 millionOptionable

Recent News About These Companies

MannKind diversifies pipeline with $360M buy
Maxim Group Downgrades scPharmaceuticals (NASDAQ:SCPH) to Hold

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$5.17 -0.25 (-4.61%)
Closing price 04:00 PM Eastern
Extended Trading
$5.16 0.00 (-0.10%)
As of 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Eliem Therapeutics stock logo

Eliem Therapeutics NASDAQ:ELYM

$2.23 -0.07 (-3.04%)
As of 08/29/2025

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Monte Rosa Therapeutics stock logo

Monte Rosa Therapeutics NASDAQ:GLUE

$4.92 +0.12 (+2.50%)
Closing price 04:00 PM Eastern
Extended Trading
$4.91 -0.01 (-0.20%)
As of 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

scPharmaceuticals stock logo

scPharmaceuticals NASDAQ:SCPH

$5.51 +0.01 (+0.18%)
Closing price 04:00 PM Eastern
Extended Trading
$5.50 0.00 (-0.09%)
As of 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.